Home › Minerva Biotechnologies Licenses Sendai Virus Technology For Stem Cell Generation
 

Keywords :   


Minerva Biotechnologies Licenses Sendai Virus Technology For Stem Cell Generation

2015-09-02 07:10:05| drugdiscoveryonline News Articles

Minerva Biotechnologies and ID Pharma Co., Ltd. (formerly DNAVEC) announced recently that they have signed an agreement granting Minerva worldwide rights to use and commercialize their non-integrating Sendai virus vectors, together with Minerva’s proprietary technology, for generating Induced Pluripotent Stem (iPS) cells

Tags: technology cell generation virus

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.11Tropical Storm Sara Graphics
15.11Tropical Storm Sara Forecast Discussion Number 8
15.11Tropical Storm Sara Wind Speed Probabilities Number 8
15.11Tropical Storm Sara Public Advisory Number 8
15.11 20213 105S P7905-P
15.11 ()
15.11Mizuno Energy 25.5
15.11
More »